Blogs

Challenging Early-Stage Fundraising Environment Requires a Change in Thinking Biotechs setting out on their fundraising journey will benefit from thinking deeply about the most appropriate indications for their assets. Indication…

Challenging Early-Stage Fundraising Environment Requires a Change in Thinking Clinical Development Plans (CDPs) are developed using multidisciplinary expertise. Early input from clinical development experts with the relevant therapy area and…

Challenging Early-Stage Fundraising Environment Requires a Change in Thinking In the current tightly-constrained funding environment, a carefully thought out TPP created utilizing cross-functional expert input that details the differentiated positioning…

Recent breakthroughs in Ribonucleic Acid (RNA)-based drug design and, more recently, the use of mRNA vaccines against COVID-19 have inspired a revival of interest in the therapeutic potential of RNA.…

“Regulatory flexibility” allows some drugs to be approved based on a single adequate and well-controlled clinical trial with confirmatory evidence. This regulatory pathway can be highly valuable when developing drugs…